

**Minutes of the 2026 Annual General Meeting of Shareholders of  
Master Style Public Company Limited**

---

The Meeting was held on 23 April 2026, at 10:00 a.m. at the conference room, Building 3 of Master Style Public Company Limited, No. 99/19 Sukhothai Road, Dusit Sub-district, Dusit District, Bangkok.

The Company provided shareholders the opportunity to propose agendas to be included in the meeting agenda, and to nominate qualified individuals for consideration and election as directors through the advance nomination process on the Company's website from 4 December 2025 to 31 January 2026, and it appeared that no shareholders proposed any agendas to be included in the meeting agenda, and no one nominated any individuals for election as the Company's directors.

For this Meeting, the Company has arranged for video recording of the Meeting to be used for preparing the minutes and for publicizing the shareholders' meeting through electronic and media, photographs and video footage of the Meeting may include images of shareholders who attended the Meeting and may also display the names of shareholders, in accordance with the objectives of the shareholders' meeting.

**Directors in attendance:**

- |                                 |  |
|---------------------------------|--|
| 1. Dr. Jedsada Chokdamrongsuk   | Chairman of the Board of Directors and Independent Director  |
| 2. Mr. Chakkrit Parapuntakul    | Independent Director, Chairman of the Audit Committee and Member of the Nomination and Remuneration Committee                                  |
| 3. Mr. Vichate Tantiwanich      | Independent Director, Member of the Audit Committee and Chairman of the Nomination and Remuneration Committee                                  |
| 4. Mr. Thanawat Lertwattanak    | Independent Director, Member of the Audit Committee and Chairman of the Risk Management Committee  |
| 5. Mr. Nutthirutt Wanwimonphong | Independent Director and Member of the Audit Committee   |
| 6. Dr. Raweewat Maschamadol     | Director, Member of the Risk Management Committee, Member of the Nomination and Remuneration Committee and Chairman of the Executive Committee |
| 7. Ms. Lapasrada Lertpanurot    | Director, Member of the Risk Management Committee, Member of the Executive Committee and Chief Executive Officer                               |
| 8. Mr. Phisut Numsa             | Director, Member of the Executive Committee and Chief Financial Officer  |

The directors attended the meeting were equivalent to 100 % of total directors.

**Directors in absence**

-None-

**Other Attendees:**

- |                                    |   |
|------------------------------------|---|
| 1. Ms. Prapawarin Longngam         | Vice Chief Executive Officer                    |
| 2. Mr. Chanin Panichpanth          | Chief Sales and Marketing Officer               |
| 3. Mr. Nutchapol Yainagnan         | Vice Chief Financial Officer                    |
| 4. Mr. Puvarart Jangjamyarn        | Vice Chief Administrative Officer               |
| 5. Dr. Rati Diwitaya               | Vice Chief Operating Officer                    |
| 6. Ms. Manee Rattanabunnakit       | Auditor from EY Office Limited                  |
| 7. Ms. Warinporn Roengrongthirunya | Auditor from EY Office Limited                  |
| 8. Ms. Natanich Techavoraprasert   | Auditor from EY Office Limited                  |
| 9. Mr. Sathianpong Phanchalam      | Legal advisor from Manunya & Associates Limited |
| 10. Ms. Sawitri Sirawacharapong    | Legal advisor from Manunya & Associates Limited |

Mr. Pharanwat Siraphatthanant, acted as a moderator of the Annual General Meeting of Shareholders. welcomed the attendees to the 2026 Annual General Meeting of Shareholders of Master Style Public Company Limited and introduced directors, executives, auditors, and legal advisors as the names listed above.

At the commencement of the Meeting, there were 21 shareholders attended the Meeting in person, representing 176,144,175 shares, and 12 shareholders attended by proxy, representing 1,649,548 shares. A total of 33 participants attended the Meeting, representing an aggregate of 177,793,723 shares, equivalent to 58.9283% of the total number of issued shares of the Company. The total number of issued shares of the Company was 301,711,736 shares, thereby a quorum was constituted according to the Company's Articles of Association.

Dr. Jedsada Chokdamrongsuk, Chairman of the Board of Directors, presided as the Chairman of the Meeting, opened the 2025 Annual General Meeting of Shareholders and assigned Mr. Pharanwat Siraphatthanant to clarify the meeting proceedings guidelines and the procedures of voting of shareholder for each agenda as follows:

1. Shareholder who attended the Meeting in person and proxies who has been authorized to vote at the Meeting will receive a ballot upon registration for the Meeting.
2. The Meeting will proceed with the agendas in the order set out in the Invitation Letter. For each agenda item, information will be presented, followed by a Q&A session where shareholders are given the opportunity to ask questions or express opinions before a vote is cast. Shareholders or proxies wishing to inquire or comment are requested to raise their hands and state their full

name. In the case of a proxy, the name of the shareholder whom you represent must also be stated to the Meeting on every occasion.

3. After acknowledging the details of each agenda. Any shareholder who Disapproved or Abstained on any agenda item. Please cast vote on the ballot received from the staff during the registering, then submitted it back to the Company's staff. Any shareholders who voted to Disapproved or Abstained, please raise your hands so that the Company's staff could collect your ballots. In this regard, for Agenda 5, the appointment of directors replacing those who retire by rotation, the Company would individually nominate for the Meeting to vote.
4. Each shareholder had one vote per share. Any shareholder who had a particular interest in any agenda would not have the right to vote on that agenda.
5. Vote Counting

Agenda 1 and Agenda 2 were the agenda for acknowledgment. Therefore, it did not require a vote.

Agenda 3, 4, 5 and Agenda 7 required the majority votes of the shareholders in attendance and casting their votes.

Agenda 6 must be approved with a vote of not less than two-thirds of the total number of votes of shareholders who attended the Meeting; and

The Company would deduct the votes of Disapproved and Abstained from the total number of votes in the Meeting. The remaining would be considered as votes of Approved for that agenda. In this regard, in case no one expressed oppositions or provided any different opinion, it shall be deemed that the Meeting had resolved or approved the agenda unanimously. In order to avoid wasting time while waiting for voting, the next agenda will be considered. Additionally, the following cases will be considered voided ballots as follows:

- (1) A ballot with more than one box marked, or no box marked at all, which indicates how the vote should be cast.
- (2) A ballot with a crossed-out without a signature.
- (3) A ballot without a signature

The Company will not count voided ballots as the base for calculating votes, except for Agenda 6 where voided ballots are counted as the vote base for the vote calculation.

For shareholders who granted proxies to another person to attend the Meeting on their behalf and cast their votes in the proxy form. The Company has already recorded the votes as specified by the shareholders in the proxy form.

Furthermore, the Company has implemented the e-Proxy Voting system of Thailand Securities Depository Company Limited (TSD) to facilitate and provide an additional channel for appointing Independent Directors to attend the shareholders' meeting as proxies. Shareholders can exercise their voting rights by logging into the TSD Investor Portal system, selecting the "Other Transactions" menu, then selecting the topic "Proxy/Voting for Shareholders' Meeting" and selecting "Create-Edit-Cancel Transaction." After that, shareholders must verify their identity according to the procedures. Once the identity verification is complete, shareholders must select the Independent Director to be appointed as their proxy and click to cast their votes for each agenda item. When all agendas are completed, the system will display the Proxy Form for review. After that, press the "Close" button on the image of Proxy Form B.

**Agenda 1 To acknowledge the minutes of the 2025 Annual General Meeting of Shareholders.**

The Chairman assigned Mr. Pharanwat Siraphatthanant, to report this agenda to the Meeting.

Mr. Pharanwat Siraphatthanant, proposed the Meeting to acknowledge the 2025 Annual General Meeting of Shareholders, held on 23 April 2025, which the copy of the minutes was accurately recorded in accordance with resolutions of the shareholder's meeting. The Company has been submitted to the Stock Exchange of Thailand and the Ministry of Commerce within the period under the law and related regulations including published through the Company's website for disclosure to shareholders and general investors, and it appeared that no one required for any revision.

The Board of Directors has considered and deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to acknowledge the Minutes of the 2025 Annual General Meeting of Shareholders, held on April 23, 2025. The Board of Directors is of the opinion that the minutes were recorded correctly in accordance with the resolutions of the meeting. A copy of the said minutes is provided in Enclosure 1.

The Company provided the shareholders with the opportunity for any inquiry details and express additional comments. It appeared that no one raised any inquiries and comments.

When no one raised additional inquiry, the Company proposed the Meeting to acknowledge the minutes of the 2025 Annual General Meeting of Shareholders.

**Resolution** The Meeting acknowledged the minutes of the 2025 Annual General Meeting of Shareholders as proposed.

## Agenda 2 To consider and acknowledge the Company's 2025 operating result

The Chairman assigned Mr. Phisut Numsa, Chief Financial Officer, to report the Company's 2025 operating result to the Meeting for acknowledgement.


Mr. Phisut Numsa summarized the Company's operating result as follows:

In 2025, the Company had revenues from hospital operations of 1,884.83 million baht, representing a decrease of 11.72%. Although the Company's revenues from hospital operations had previously grown continuously, the current decrease was mainly due to a decline in the number of patients. This resulted from several factors, including the economic slowdown, weakened consumer purchasing power, and intense price competition.


Revenue structure from hospital operations	2025		2024	
	Million Baht	%	Million Baht	%
1. Revenue from surgery	1,483.76	78.1	1,765.66	81.9
2. Revenue from skin care	122.93	6.5	113.55	5.3
3. Revenue from hair transplantation and hair care	145.26	7.6	124.59	5.8
4. Revenue from care after surgery	75.01	3.9	83.03	3.9
5. Revenue from other hospital operations	57.88	3.0	48.25	2.2
<b>Total revenue from hospital operations</b>	<b>1,884.84</b>	<b>99.2</b>	<b>2,135.08</b>	<b>99.1</b>
<b>Other Revenue</b>	14.46	0.8	21.45	0.9
<b>Gross Revenue</b>	<b>1,899.30</b>	<b>100.0%</b>	<b>2,156.53</b>	<b>100.0%</b>

In 2025, the Company had the cost of hospital operations of 868.6 million baht, or 46.08% of the revenue from hospital operations. The primary costs of hospital operations included doctor fees, medicines, medical supplies, and consumables, as well as compensation for nurses and medical personnel, including depreciation from the increased number of operating rooms and medical equipment.

The gross profit from hospital operations was 1,016.26 million baht, representing a gross profit margin of 53.92%. This reflects a decrease of 263.34 million baht, or 20.58%, primarily due to the increase in doctor compensation.



In 2025, the Company had sales and administrative expenses of 756.51 million baht, representing 40.14% of total revenue. The increase in expenses was mainly due to higher marketing costs from online advertising, following the announcement by the Department of Health Service Support regarding medical advertisements. For the year 2025, the Company recorded a net profit of 198 million baht, representing a net profit margin of 10.5%. This reflects a decrease of 309.8 million baht, or 61%.



#### Financial position as of December 31, 2025

Total assets amounted to 4,286 million baht. As of December 31, 2025, the Company's primary assets consisted of investments in joint ventures, property, plant and equipment, right-of-use assets, and inventories. These items collectively accounted for 90% of the total assets as of December 31, 2025.

Total liabilities amounted to 845 million baht, representing 19% of total liabilities and shareholders' equity. As of December 31, 2025, the Company's primary liabilities consisted of trade and other payables, deferred income, accrued income tax, and lease liabilities, including loans from financial institutions. These items collectively accounted for 97% of the total liabilities as of December 31, 2025.

Shareholders' equity amounted to 3,451 million baht, representing 81% of total liabilities and shareholders' equity. Shareholders' equity consisted of issued and paid-up share capital, share premium, and retained earnings, including both legal reserve and unappropriated retained earnings.

The Board of Directors has considered and deemed it appropriate to propose that the Annual General Meeting of Shareholders acknowledge the Company's operating results for the year 2025, as per the details provided above.

The Company provided an opportunity for shareholders to inquire about the details and offer additional suggestions.

- Mr. Wiwat Khusakul, A proxy holder, on behalf of Ms. Siriporn Mukphon: Inquired about the reasons behind the significant decline in other income.

Mr. Phisut Numsa, Chief Financial Officer: Explained that the decrease resulted from adjustments to the Company's liquidity management strategy, whereby funds were reallocated to investments that generate returns in other forms, such as short-term debt instruments and investments in joint ventures

**Resolution** The meeting acknowledged the Company's 2025 operating result as proposed.

**Agenda 3 To consider the approve the audited financial statements for the fiscal year ended 31 December 2025**

The Chairman assigned Mr. Phisut Numsa, Chief Financial Officer, to summarize details of the Company's consolidated financial statements summarized as follows:

The financial position and overall performance of Master Style Public Company Limited and its subsidiaries for the year ended 31 December 2025, as follows:

	31 December 2025	31 December 2024	Change (Increase/Decrease)	
			Amount	Percentage (%)
<b>Assets</b>				
Current Assets	367.34	346.17	21.17	6.12
Non-Current Assets	3,918.79	4,159.50	(240.71)	(5.79)
<b>Total Assets</b>	<b>4,286.13</b>	<b>4,505.67</b>	<b>(219.54)</b>	<b>(4.87)</b>
<b>Liabilities</b>				
Current Liabilities	415.58	475.95	(60.37)	(12.68)
Non-Current Liabilities	419.27	534.99	(115.72)	(21.63)
<b>Total Liabilities</b>	<b>834.85</b>	<b>1,010.94</b>	<b>(176.09)</b>	<b>(17.42)</b>
<b>Shareholders' Equity</b>	<b>3,451.28</b>	<b>3,494.73</b>	<b>(43.45)</b>	<b>(1.24)</b>
<b>Total Liabilities and Shareholders' Equity</b>	<b>4,286.13</b>	<b>4,505.67</b>	<b>(219.54)</b>	<b>(4.87)</b>

(Unit: Million Baht)	The fiscal year ended 31 December 2025		Change (Increase/Decrease)	
	2025	2024	Amount	Percentage (%)
Revenue from hospital operations	1,884.83	2,135.08	(250.25)	(11.72)
Cost of hospital operations	868.56	855.48	13.08	1.53
<b>Gross profit</b>	<b>1,016.27</b>	<b>1,279.60</b>	<b>(263.33)</b>	<b>(20.58)</b>
Other income	14.45	21.45	(7.00)	(32.63)
Selling expenses	432.28	384.39	47.89	12.46
Administrative expenses	324.23	317.85	6.38	2.01
<b>Operating profit</b>	<b>248.21</b>	<b>598.81</b>	<b>(350.60)</b>	<b>(58.55)</b>
Share of profit from investments in joint ventures	24.78	36.61	(11.83)	(32.31)
Impairment loss on investment in joint venture	26.00	-	26	100
Finance income	4.38	6.13	(1.75)	(28.55)
Finance costs	(29.29)	(18.46)	10.83	58.67
<b>Profit before income tax</b>	<b>248.08</b>	<b>623.09</b>	<b>(375.01)</b>	<b>(60.19)</b>
Income tax expense	(50.08)	(115.34)	(65.25)	(56.58)
<b>Net profit for the year</b>	<b>198.00</b>	<b>507.75</b>	<b>(309.75)</b>	<b>(61.00)</b>
Other comprehensive income (loss)	(0.09)	-	(0.09)	100.00
<b>Total Comprehensive Loss</b>	<b>197.91</b>	<b>507.75</b>	<b>(309.84)</b>	<b>(61.02)</b>

The Company's financial statements for the fiscal year ended 31 December 2025, which has been audited by the Company's auditor as specified in the Annual Registration Statement/Annual Report 2025 (Form 56-1 One Report) of the Company (Part 1, Subject Management Discussion and Analysis).

The Company provided the shareholders with the opportunity for any inquiry details and express additional comments. It appeared that no one raised any inquiries and comments.

When no one raised additional inquiry, the Company proposed the Meeting to consider and approve the Company's financial statements for the fiscal year ended 31 December 2025, details appeared in the Annual Report, which was sent to the shareholders, together with the invitation letter before the Meeting.

**Resolution** The meeting considered and unanimously approved the consolidated financial statements for the year ended 31 December 2025, with the following votes:

Approved	177,793,723	votes	equal to	100.0000
Disapproved	0	votes	equal to	0.0000
Abstained	0	votes		
Voided ballot	0	votes		

**Agenda 4 To consider and approve the payment of dividends in respect of the Company's operating results of the year 2025**

Mr. Phisut Numsa, Chief Financial Officer, informed the Meeting that according to the Company's operating results for the fiscal year ended 31 December 2025, according to the separate financial statements for the fiscal year ended 31 December 2025. which has been audited by the auditor, the Company has retained earnings of 794,186,824 Baht and net profit of 220,742,877 Baht.

Additionally, the Company has a policy to pay dividends at a rate of not less than 50% of the net profit from the Company's separate financial statements, after the deduction of corporate income tax and the allocation of all types of reserves as prescribed by law and the Company's Articles of Association. However, the dividend payment may be subject to change depending on necessity and other appropriateness as the Board of Directors deems fit, taking into account various factors for the benefit of the shareholders. Such dividend payment must not materially affect the Company's operations, financial position, liquidity, investment plans in each period, and other factors related to the Company's management.

The Board of Directors' Meeting deemed it appropriate to propose to the Shareholders' Meeting to consider and approve the dividend payment from the net profit of the operating results ended December 31, 2025, to the shareholders at the rate of 0.40 Baht per share for 301,711,736 shares, totaling 120,684,694.40 Baht. The Record Date to determine the list of shareholders entitled to receive the dividend is set for March 17, 2026, and the dividend payment date is scheduled for May 12, 2026.

This dividend payment rate is equivalent to 54.67 percent of the net profit according to the separate financial statements, which is in accordance with the Company's dividend policy. Under this policy, the Company is to pay dividends at a rate of not less than 50 percent of the net profit after deduction of corporate income tax and legal reserve allocation. However,

as the Company has already fully allocated the legal reserve to 10 percent of its registered capital, no further legal reserve allocation is required.

The Company provided the shareholders with the opportunity for any inquiry details and express additional comments. It appeared that no one raised any inquiries and comments.

When no one raised additional inquiry, the Company proposed the Meeting to consider and approve the dividend payment from the net profit of the operating results ended December 31, 2025, to the shareholders at the rate of 0.40 Baht per share for 301,711,736 shares, totaling 120,684,694.40 Baht.

**Resolution** The Meeting considered and resolved to approve the dividend payment from the net profits of the operating results ended as of 31 December 2025 to the shareholders at the rate of 0.40 Baht per share, for 301,711,736 shares, totaling 120,684,694.40 Baht, as proposed, with the majority votes of the shareholders in attendance and casting their votes as follows:

Approved	177,793,723	votes	equal to	100.0000
Disapproved	0	votes	equal to	0.0000
Abstained	0	votes		
Voided ballot	0	votes		

**Agenda 5 To consider the approve the appointment of directors replacing those retire by rotation**

Mr. Pharanwat Siraphatthananont, Informed the Meeting that, pursuant to Section 71 of the Public Limited Companies Act B.E. 2535 (1992) and Article 18 of the Company's Articles of Association, at every Annual General Meeting of Shareholders, one-third of the directors, or the number nearest to one-third, shall retire from office. The directors to retire in the first and second years following the Company's registration shall be determined by drawing lots. In subsequent years, the directors who have been in office the longest shall retire. For the 2026 Annual General Meeting, the directors who are due to retire by rotation are as follows:

1. Dr. Jedsada Chokdamrongsuk Independent Director
2. Dr. Raweevat Maschamadol Director
3. Mr. Nutthirutt Wanwimonphong Independent Director

The Nomination and Remuneration Committee has screened and considered the candidates through the Company's established nomination process, the Board structure,

and the individual qualifications of the three directors. The Committee found that their qualifications comply with the Public Limited Companies Act, the Securities and Exchange Act, and other relevant laws. They possess the appropriate qualifications, knowledge, skills, and experience for the Company's business operations. Furthermore, their past performance as directors has been highly beneficial to the Company.

In this regard, all three directors do not possess any prohibited characteristics, nor do they operate or hold shares in any business that competes with the Company's operations. Additionally, the Nomination and Remuneration Committee has considered that the persons nominated as Independent Directors are capable of expressing opinions independently regarding the Company's operations and meet all regulatory requirements for independent directors.

Therefore, the Committee deemed it appropriate to propose the re-appointment of these three directors for another term. The Board of Directors' Meeting (excluding the interested directors) has carefully and prudently reviewed the matter and deemed it appropriate to propose that the Shareholders' Meeting consider and approve the re-appointment of the following directors who are retiring by rotation:

- |                                 |                      |
|---------------------------------|----------------------|
| 1. Dr. Jedsada Chokdamrongsuk   | Independent Director |
| 2. Dr. Raweevat Maschamadol     | Director             |
| 3. Mr. Nutthirutt Wanwimonphong | Independent Director |

In this regard, the persons nominated on this occasion have undergone the screening process through the established nomination procedures. They possess qualifications that are in accordance with the Public Limited Companies Act, the Securities and Exchange Act, and other relevant regulations (if any), and are suitable for the Company's business operations. Furthermore, the Independent Directors possess qualifications that meet the requirements relating to independent directors as prescribed by relevant laws.

The detailed profiles of all three directors are as presented to the Meeting and as appeared in the Invitation Letter to the Shareholders' Meeting, Enclosure 3.

The Company provided the shareholders with the opportunity for any inquiry details and express additional comments. It appeared that no one raised any inquiries and comments.

When no one raised additional inquiry, the Company proposed the Meeting to consider and approve the appointment of directors replacing those retired by rotation to be re-appointed for another term by proposing individually to the Meeting for consideration and approval.

**Resolution** The Meeting considered and resolved to approve the appointment of the above directors, which are directors who must retire by rotation re-appointed as a director of the Company for another term, with the majority votes of the shareholders in attendance and casting their votes, as the follows:

1.	Dr. Jedsada Chokdamrongsuk	Independent Director			
	Approved	177,605,152	votes	equal to	100.0000
	Disapproved	0	votes	equal to	0.0000
	Abstained	188,571	votes		
	Voided ballot	0	votes		
2.	Dr. Raweewat Maschamadol	Director			
	Approved	40,460,775	votes	equal to	100.0000
	Disapproved	0	votes	equal to	0.0000
	Abstained	137,332,948	votes		
	Voided ballot	0	votes		
3.	Mr. Nutthirutt Wanwimonphong	Independent Director			
	Approved	177,793,723	votes	equal to	100.0000
	Disapproved	0	votes	equal to	0.0000
	Abstained	0	votes		
	Voided ballot	0	votes		

**Agenda 6 To consider and approve the determination of the director's remuneration for the year 2026**

Mr. Pharanwat Siraphatthananont, informed that the Nomination and Remuneration Committee has conducted a survey on the director's remuneration for the year 2026 and considered it in accordance with the criteria and policies determined by the Board of Directors with consideration of the responsibility and performance of the Board of Directors as well as the comparative data refer to other companies in the same industry with similar sizes and characteristics of business, including the Directors' Compensation Survey by the Thai Institute of Directors Association (IOD), in which found that the directors' remuneration determined by the Company is close to the market average.

The Meeting of the Board of Directors deemed it appropriate to propose to the shareholders' meeting to consider and approve the Directors' remuneration and sub-committees' remuneration for the year 2026 in the form of meeting allowance, monthly remuneration, bonus, and yearly benefits. Details appear in the invitation letter of the Meeting, which was sent to the shareholders before the Meeting as follows:

Position	Meeting Allowance (per time)	Monthly Remuneration	Bonus	Yearly Benefits
Chairman of the Board of Director	20,000	25,000	25% of dividends paid to shareholders, but not exceeding 5,000,000 Baht, which the Board of Directors will further consider and allocate as appropriate.	700,000
Directors	15,000	15,000		400,000
Chairman of the Audit Committee	15,000	-		-
Members of the Audit Committee	12,000	-		-
Chairman of the Nomination and Remuneration Committee	15,000	-		-
Members of the Nomination and Remuneration Committee	12,000	-		-
Chairman of the Risk Management Committee	15,000	-		-
Members of the Risk Management Committee	12,000	-		-

- Remark:** 1. Benefits means the amount of money paid for using services at the hospital for directors and their families. (spouse and children), for the Chairman of the Board of Directors in the amount of not exceeding 700,000 Baht and for the Company's and Directors in the amount of not exceeding 400,000 Baht, effective on 1 January 2026.
2. Executive directors do not receive a monthly remuneration.

In this regard, the Board of Directors and sub-committees of the Company received no other benefit than meeting allowance, monthly remuneration, bonus, and yearly benefits as detailed above.

The details of the comparison table for directors' remuneration for the year 2026 (the proposed year) and 2025 are as shown in the presentation slides and as appeared in the Invitation Letter to the Shareholders' Meeting as follows:

Position/Components of Remuneration	Meeting Allowance (per time/baht)		Monthly Remuneration (baht)		Bonus		Yearly Benefits (baht)	
	2026 (As Proposed)	2025	2026 (As Proposed)	2025	2026 (As Proposed)	2025	2026 (As Proposed)	2025
Chairman of the Board of Director	20,000	20,000	25,000	25,000	0.25% of	0.25% of	700,000	700,000
Directors	15,000	15,000	15,000	15,000	dividends paid to shareholders,	dividends paid to shareholders,	400,000	400,000
Chairman of the Audit Committee	15,000	15,000	-	-	but not	but not	-	-
Members of the Audit Committee	12,000	12,000	-	-	exceeding	exceeding	-	-
Chairman of the Nomination and Remuneration Committee	15,000	15,000	-	-	5,000,000 baht, which the Board of Directors will	5,000,000 baht, which the Board of Directors will	-	-
Members of the Nomination and Remuneration Committee	12,000	12,000	-	-	further consider and allocate as appropriate.	further consider and allocate as appropriate.	-	-
Chairman of the Risk Management Committee	15,000	15,000	-	-			-	-
Members of the Risk Management Committee	12,000	12,000	-	-			-	-

The Company provided the shareholders with the opportunity for any inquiry details and express additional comments. It appeared that no one raised any inquiries and comments.

When no one raised additional inquiry, the Company proposed the Meeting to consider the approval of the determination of the director's remuneration for the year 2026.

**Resolution** The Meeting considered and resolved to approve the determination of the director's remuneration for the year 2026 as proposed, with the votes of not less than two-thirds of total votes of the shareholders who attend the meeting as follows:

Approved	177,793,723	votes	equal to	100.0000
Disapproved	0	votes	equal to	0.0000
Abstained	0	votes	equal to	0.0000
Voided ballot	0	votes	equal to	0.0000

**Agenda 7 To consider and approve the appointment of auditors and audit's remuneration for the year 2026**

Mr. Phisut Numsa, Chief Financial Officer, informed that the Audit Committee has considered the appointment of the Company's auditor based on the independence of auditors and their remuneration and deemed to propose the appointment of

1. Mr. Piya Chaipruckmalakarn Certified Public Accountant No.7544 or
2. Ms. Siriwan Suratepin Certified Public Accountant No.4604 or
3. Mr. Wichart Lokatekrawee Certified Public Accountant No.4451

From EY Office Limited as the Company's auditor for the year 2026. Any person shall be responsible for auditing and expressing opinion on the financial statements of the Company. In case the above-mentioned certified public accountants are unable to perform their duty, EY Office Limited is authorized to choose any of its certified public accountants as a substitute to audit and express opinions on the Company's financial statements. The auditors listed above do not provide any other services to the Company and have no relationship or interest with the Company/subsidiary/executive/ major shareholders, or those related to such persons in any way. Therefore, they are independent in auditing and expressing their opinions on the Company's financial statements. Additionally, the determination of the audit fee for the year 2026 in the amount of not exceeding 3,600,000 Baht, excluding other expenses, which will be paid on actual.

In this regard, the subsidiary, Master Innovation Company Limited, does not use the same audit firm as the Company. However, the Board of Directors will ensure that the financial statements are prepared and completed within the specified timeframe.

The Company provided the shareholders with the opportunity for any inquiry details and express additional comments. It appeared that no one raised any inquiries and comments.

When no one raised additional inquiry, the Company proposed the Meeting to consider the approval of the appointment of auditors and their remuneration for the year 2026 as proposed.

**Resolution** The Meeting considered and resolved to approve the appointment of auditors and their remuneration for the year 2026 as proposed, with the majority votes of the shareholders in attendance and casting their votes as follows:

Approved	177,793,723	votes	equal to	100.0000
Disapproved	0	votes	equal to	0.0000
Abstained	0	votes		
Voided ballot	0	votes		

#### **Agenda 8 Other business (if any)**

The Chairman asked the shareholders who attended the Meeting, whether they would like to propose another agenda for this Meeting. When no one proposed any other matter to the Meeting, the chairman gave the opportunity to shareholders to ask further inquiry, which the shareholders made inquiries as follows:

1. Mr. Boonchu Juramongkol, A proxy holder, on behalf of Mr. Phatcharadham Phonakkarawat, inquired that:

1.1 Resignation of the Chief Executive Officer (CEO)

- Ms. Lapasrada Lertpanurot (CEO): Explained that her decision to resign was made after thorough consideration and reflected the appropriate timing for the Company's organizational development. Those strengths lie in managing small enterprises and that had successfully guided the Company from a small business to a stable organization that ultimately achieved listing on the Stock Exchange.
- To ensure long-term continuity and sustainability, had held in-depth discussions with the management team and Dr. Raweewat Maschamadol (CEO Group) regarding the Company's future direction. Emphasized that transferring leadership to the founding group, who possess deep understanding of the Company's context and culture, along with strong strategic decision-making capabilities, would be a key factor in driving the Company's next phase of accelerated growth and maximizing shareholder value.

1.2 Future Operating Plan and Vision

- Dr. Raweewat Maschamadol: Confirmed the Group's readiness to manage the business amid economic uncertainties and external factors (such as geopolitical conflicts and past pandemic-related impacts). The operational approach is as follows:

1.2.1 Management: Focus on preparedness to respond to rapidly changing situations, including the application of AI technologies to enhance operational efficiency.

1.2.2 Joint Venture Investments: Emphasize executing the established plans and providing full support to business partners.

1.2.3 International Market Expansion: Currently in the process of identifying business partners to expand the Company's growth base at the global level.

1.3 Acting CEO and CEO Succession

- Dr. Raweewat Maschamadol: Stated that during the period serving as Acting CEO, I will act as a mentor and make key decisions in the best interests of the Company. Added that the Company has a clear succession plan in place, which is currently being implemented according to the established timeline.

1.4 Addressing Underperformance of Joint Ventures

- Mr. Phisut Numsa, Chief Financial Officer: Noted that the Company conducts regular due diligence and prepares financial projections. If performance falls short of targets, the Company will review the plans with its partners and adjust strategies as appropriate.
2. Ms. Sumana Rujichansiri, A proxy holder, on behalf of Thai Investors Association, inquired that:
- 2.1 Business Expansion Strategy and Cost Management
- Dr. Raweewat Maschamadol: Stated that the Company prioritizes effective cost management while continuing to operate with a clear focus on its core organizational objectives
- 2.2 Impact of Negative News Related to the Aesthetic Surgery Business
- Dr. Raweewat Maschamadol: Clarified that the Company upholds transparent operating standards and does not change personnel names to avoid responsibility as alleged in the news. With respect to the accident that became a matter of public concern, the Company has not observed any material negative impact on its operations.

There were no shareholders who would like to inquire or give any other opinions, the Chairman closed the meeting.

The Meeting was adjourned at 11.30 a.m.

Mr. Jedsada Chokdamrongsuk  
Chairman of the Board